Mark Joseph Chicarelli

TL;DR: The discovery of the clinical development candidate MRTX849 as a potent, selective covalent inhibitor of KRASG12C is described.

TL;DR: In this article, the authors provided compounds of formula I that are useful as potent and selective inhibitors of 11-beta hydroxysteroid dehydrogenase 1 (HBDE) and a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.

TL;DR: A series of tetrahydropyridopyrimidines are discovered as irreversible covalent inhibitors of KRAS-G12C with in vivo activity and the PK/PD and efficacy of compound 13 will be highlighted.

TL;DR: In this article, the authors used Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof for the treatment of hyperproliferative, pain and inflammatory diseases.

TL;DR: In this article, compounds of the General Formula I: stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X 1, X 2, X 3 and X 4 have the meanings given in the specification, which are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET Kinase.